• Home

    • Overview
    • The partners
  • About the Project

    • The Clinical Need
  • What can we do

    • Gene therapy
    • Therapeutic genes
    • Which genes are we using
    • Safety of gene therapy
  • Clinical Trial

    • Study design
    • End points
    • Exercise test
    • Timelines
    • Is It Safe?
    • Our previous study
  • Contact Us

  • News

  • Members Area

  • More

    Use tab to navigate through the menu items.

    POHJOIS-SAVON SAIRAANHOITOPIIRIN KUNTAYHTYMA Finland represented by Seppo Ylä-Herttuala

    QUEEN MARY UNIVERSITY OF LONDON United Kingdom represented by Anthony Mathur

    UNIVERSITY COLLEGE LONDON United Kingdom represented by Kris Thielemans

    MEDIZINISCHE UNIVERSITAET WIEN Austria represented by Mariann Pavone-Gyöngyösi

    SERVICIO MADRILENO DE SALUD Spain represented by Ricardo Sanz-Ruiz

    FINVECTOR VISION THERAPIES OY Finland represented by Timo Ristola

    SLASKI UNIWERSYTET MEDYCZNY W KATOWICACH Poland represented by Wojtek Wojakowski

    REGION HOVEDSTADEN Denmark represented by Jens Kastrup

    A2F ASSOCIATES LIMITED United Kingdom represented by James Holder

    ​

    1.png
    QMUL.png
    UCL.png
    Vienna.png
    Spain.png
    Finvector.png
    Poland.png
    Denmark.png
    A2F.png

    This project has received funding from the European Union's Horizon 2020 research and innovation progamme under grant agreement No 731532.

    ©2020 by ReGenHeart